Nisa Investment Advisors LLC Sells 2,560 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Nisa Investment Advisors LLC lowered its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 23.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,315 shares of the company’s stock after selling 2,560 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Medpace were worth $2,549,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. DekaBank Deutsche Girozentrale grew its stake in Medpace by 39.6% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 34,857 shares of the company’s stock valued at $10,801,000 after buying an additional 9,896 shares during the last quarter. New York State Teachers Retirement System grew its stake in Medpace by 0.3% in the 4th quarter. New York State Teachers Retirement System now owns 33,711 shares of the company’s stock valued at $10,333,000 after buying an additional 100 shares during the last quarter. Campbell Newman Asset Management Inc. grew its stake in Medpace by 0.4% in the 4th quarter. Campbell Newman Asset Management Inc. now owns 11,095 shares of the company’s stock valued at $3,401,000 after buying an additional 46 shares during the last quarter. International Assets Investment Management LLC grew its stake in Medpace by 248,773.8% in the 4th quarter. International Assets Investment Management LLC now owns 104,527 shares of the company’s stock valued at $32,041,000 after buying an additional 104,485 shares during the last quarter. Finally, Riverbridge Partners LLC grew its stake in Medpace by 7.1% in the 4th quarter. Riverbridge Partners LLC now owns 652,384 shares of the company’s stock valued at $199,975,000 after buying an additional 43,197 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Insider Activity at Medpace

In related news, major shareholder Medpace Investors, Llc sold 50,000 shares of Medpace stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $391.75, for a total transaction of $19,587,500.00. Following the completion of the transaction, the insider now directly owns 5,539,947 shares of the company’s stock, valued at approximately $2,170,274,237.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Medpace news, CEO August J. Troendle sold 100,000 shares of the business’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total value of $41,298,000.00. Following the completion of the transaction, the chief executive officer now directly owns 4,833,019 shares of the company’s stock, valued at $1,995,940,186.62. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Medpace Investors, Llc sold 50,000 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $391.75, for a total transaction of $19,587,500.00. Following the completion of the transaction, the insider now directly owns 5,539,947 shares of the company’s stock, valued at $2,170,274,237.25. The disclosure for this sale can be found here. Insiders sold 189,340 shares of company stock valued at $76,651,647 in the last ninety days. Insiders own 25.70% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. UBS Group upgraded shares of Medpace from a “neutral” rating to a “buy” rating and raised their price target for the stock from $282.00 to $452.00 in a research report on Thursday, February 15th. StockNews.com lowered shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, March 23rd. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Medpace in a research report on Monday, March 18th. They set a “hold” rating and a $395.00 target price on the stock. Finally, Robert W. Baird lifted their target price on shares of Medpace from $312.00 to $408.00 and gave the company an “outperform” rating in a research report on Wednesday, February 14th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, Medpace has an average rating of “Moderate Buy” and a consensus price target of $382.00.

Medpace Stock Down 1.8 %

Shares of MEDP stock opened at $395.00 on Friday. Medpace Holdings, Inc. has a 12-month low of $185.43 and a 12-month high of $419.42. The company has a market capitalization of $12.24 billion, a P/E ratio of 44.48, a P/E/G ratio of 2.13 and a beta of 1.38. The firm has a 50-day moving average price of $388.79 and a 200 day moving average price of $315.24.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, February 12th. The company reported $2.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.22 by $0.24. Medpace had a net margin of 15.00% and a return on equity of 63.98%. The firm had revenue of $498.40 million during the quarter, compared to the consensus estimate of $498.72 million. During the same period last year, the firm posted $2.12 EPS. The firm’s quarterly revenue was up 26.5% on a year-over-year basis. As a group, research analysts expect that Medpace Holdings, Inc. will post 10.53 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.